title: The impact of molecular analysis on the survival of children with embryonal tumors.
abstract: Embryonal tumors represent a heterogeneous group of malignancies characterized by poorly differentiated cells and generally aggressive behavior. Although advances in survival rates have been made in several of these tumor types, including Wilms' tumor, retinoblastoma, and medulloblastoma, survival of patients with central nervous system (CNS) embryonal tumors, including primitive neuro-ectodermal tumors (PNETs) and atypical teratoid rhabdoid tumors (AT/RT), are particularly poor. Advancing molecular analysis techniques and the development of gene expression profiles has led to the formulation of different subdivisions within many of the umbrella CNS tumor groups with clinical and prognostic implications. Some subgroups have been identified as having improved survivorships, likely not captured by large scale population data given their small numbers and relatively recent characterization. Importantly, identification of differing molecular pathways has begun to result in targeted therapies which may pave the way for even more surviving patients in the coming years.
authors.affiliation: Brain Tumor Institute, Children's National Health System, Children's National Medical Center, Washington, DC, USA.
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Drezner
authors.affiliation: Brain Tumor Institute, Children's National Health System, Children's National Medical Center, Washington, DC, USA.
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Packer
keywords: Embryonal tumors; molecular profiling; pediatrics
references.citation: Mod Pathol. 2003 Sep;16(9):930-6
references.pmid: 13679457
references.citation: Cancer. 2005 Apr 1;103(7):1457-67
references.pmid: 15712273
references.citation: J Neuropathol Exp Neurol. 2005 May;64(5):391-7
references.pmid: 15892296
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1408-14
references.pmid: 20823417
references.citation: Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
references.pmid: 21796761
references.citation: Lancet Oncol. 2012 Aug;13(8):838-48
references.pmid: 22691720
references.citation: Nature. 2012 Aug 2;488(7409):49-56
references.pmid: 22832581
references.citation: Adv Clin Exp Med. 2012 Nov-Dec;21(6):809-820
references.pmid: 23457141
references.citation: Acta Neuropathol. 2014 Aug;128(2):279-89
references.pmid: 24337497
references.citation: J Indian Assoc Pediatr Surg. 2014 Oct;19(4):201-7
references.pmid: 25336801
references.citation: Pediatr Clin North Am. 2015 Feb;62(1):225-56
references.pmid: 25435121
references.citation: Lancet Oncol. 2015 May;16(5):569-82
references.pmid: 25882982
references.citation: Pediatrics. 2015 Sep;136(3):e623-32
references.pmid: 26304823
references.citation: Transl Pediatr. 2014 Jan;3(1):12-24
references.pmid: 26835318